Kinesiophobia, Pain, Balance, Quality of Life and Mental Status in Hemodialysis Patients

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorKirsehir Ahi Evran Universitesi

About this trial

The aim of our study was to investigate the relationship between kinesiophobia and pain, balance, physical performance, quality of life and mental status in patients receiving hemodialysis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with end stage renal disease receiving hemodialysis

Receiving hemodialysis for more than 3 months

Being clinically stable

Volunteering to participate in this stud

Disqualifiers

None

Trial population

Patients with end-stage renal disease receiving hemodialysis will be enrolled in the study.

Trial design

Design model

Case-only

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

32 Participants
are grouped into 1 trial group
Group A: Hemodialysis patients

Trial outcomes

Primary outcomes

1

Kinesiophobia

It will be evaluated with the Tampa Kinesiophobia scale.The total score ranges from 17-68, with a score above 37 indicating a high degree of kinesiophobia.

Time frame
Day 1
2

Pain

Will be evaluated with a numeric rating scale. Higher scores indicate worse outcomes.

Time frame
Day 1
3

Balance

It will be assessed with a timed up and go test

Time frame
Day 1
4

Physical performance

It will be evaluated with five-repetition sit-to-stand test

Time frame
Day 1

Secondary outcomes

1

Quality of life

It will be evaluated with the Short Form-36 Quality of Life scale.The subscales rate health from 0 to 100, with 0 indicating poor health and 100 indicating good health.

Time frame
Day 1
2

Mental health

It will be assessed using the Hospital Anxiety and Depression scale. The lowest score they can get from both subscales is 0 and the highest score is 21.High scores indicate high levels of anxiety and depression

Time frame
Day 1
3

Comorbidity level

It will be evaluated with the Charlson Comorbidity Index. Total score is between 0-37. Higher scores indicate worse outcomes and higher risk of death.

Time frame
Day 1

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.